Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a “hot potato” for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat...
Main Authors: | Hyunwoo Oh, Dae Won Jun, Waqar K Saeed, Mindie H Nguyen |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2016-09-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2016-0049.pdf |
Similar Items
-
The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update
by: Aleksandra Hliwa, et al.
Published: (2021-06-01) -
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
by: Hyo Young Lee, et al.
Published: (2019-03-01) -
Evolving ideas on non-alcoholic fatty liver disease: from risk to catastrophe
by: Yu. M. Stepanov, et al.
Published: (2020-04-01) -
Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits
by: Saad Emhmed Ali, et al.
Published: (2021-02-01) -
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
by: Jong Hwa Choi, et al.
Published: (2020-10-01)